Letrostar (Letrozole)

Letrozole works by reversibly inhibiting the aromatase enzyme (CYP19A1) that converts androgens into estrogens in peripheral tissues. By blocking this conversion, circulating estradiol and estrone concentrations fall, depriving estrogen‑dependent cancer cells of a key growth signal. The effect is dose‑dependent and persists for several days after each dose.

The specific dose of Letrostar is determined by the prescribing physician based on the patient’s clinical condition, treatment stage, and individual factors. Typical adult dosing for postmenopausal breast cancer is 2.5 mg taken once daily, but the exact regimen should follow the oncologist’s order and local prescribing guidelines.

Letrozole is classified as contraindicated in pregnancy because it can interfere with fetal estrogen production. Women of childbearing potential must use effective contraception while taking the drug. Safety during breastfeeding has not been established; therefore, breastfeeding is generally discouraged during treatment with letrozole.

To request Letrostar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor, offering more potent estrogen suppression than earlier agents such as anastrozole. Compared with selective estrogen receptor modulators (e.g., tamoxifen), letrozole does not have partial agonist activity and is generally preferred for postmenopausal patients because of its higher efficacy in reducing recurrence risk, though side‑effect profiles differ.

Letrostar tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Letrostar is taken orally, usually as a single tablet swallowed whole with water. It can be taken with or without food, but consistency with respect to meals is recommended to maintain stable absorption. Patients should follow the dosing schedule prescribed by their oncologist and not miss doses without medical advice.

The most serious risks include severe bone loss leading to osteoporosis and fractures, hepatic dysfunction indicated by elevated liver enzymes, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored regularly for bone density, liver function, and any signs of hypersensitivity, and report urgent symptoms to their healthcare provider.

Letrozole is not recommended for premenopausal women, patients with known hypersensitivity to letrozole or other aromatase inhibitors, individuals with uncontrolled liver disease, or those who are pregnant or breastfeeding. Caution is also advised in patients with a history of thromboembolic events or severe cardiovascular disease, and the decision to treat should be individualized by a qualified clinician.